The estimated primary objective completion date is 31 July 2023. So really, not too long to go now. If the combo treatment shows a marked improvement to efficacy without any added toxicity, Merck might well make a move on Hervaxx. Best scenario would be an upfront licence payment with revenue sharing deal.
My thoughts exactly. July 2023 isn't that far off, and seriously, if the combo treatment shows a marked improvement in efficacy without any added toxicity then ... why in heaven's name wouldn't Merck want to make an offer? Its not as though Merck has no rivals nipping at their heals !!! Their list of rivals is growing by the day. While they have the 'lead' I would expect that they would want to keep it. This is their chance.
Here's a little Ozzie Biotec potentially offering them a more effective and SAFER treatment !
I can certainly see a nice upfront license fee and some form of a revenue sharing deal if this hits the sweet spot.
Just my opinion of course.
The estimated primary objective completion date is 31 July 2023....
-
- There are more pages in this discussion • 8,541 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $379.2M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.2¢ | 5.0¢ | $1.098M | 21.50M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 97 | 7481668 | 5.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.1¢ | 1703097 | 4 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |